Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-08-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.05.4346PMID 16921040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age.

  2005cited by this paper
• Analysis of Survival, AML Transformation, and Transfusion Independence in Patients with High-Risk Myelodysplastic Syndromes (MDS) Receiving Azacitidine Determined Using a Prognostic Model.

  2005cited by this paper
• Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

  2002influential reference
• Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

  2002cited by this paper
• Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.

  2000cited by this paper
• Report of an international working group to standardize response criteria for myelodysplastic syndromes.

  2000influential reference
• World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

  1999cited by this paper
• The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.

  1999cited by this paper
• Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

  1993influential reference
• Infection in the myelodysplastic syndromes.

  1991cited by this paper
• Proposals for the classification of the myelodysplastic syndromes

  1982influential reference

• Beyond initial response: acquired resistance to hypomethylating agents in myeloid malignancies.

  2026cites this paper
• Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

  2026cites this paper
• Temporal trends in AML incidence and mortality, with a focus on AML-related deaths among patients with myelodysplastic syndromes in the United States, 1999-2023.

  2025cites this paper
• FDA approval of imetelstat: a new era in the treatment of lower-risk myelodysplastic syndrome

  2025cites this paper
• A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML

  2025cites this paper
• Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling

  2025cites this paper
• 足疗程去甲基化药物治疗骨髓增生异常综合征：多中心回顾性研究

  2024cites this paper
• Does monetary poverty reduction through gender empowerment work?

  2024cites this paper
• Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

  2024cites this paper
• A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients

  2024cites this paper
• Epigenetic inhibitors for cancer treatment.

  2024cites this paper
• Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management

  2024cites this paper
• Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine—A Retrospective Analysis

  2024influential citation
• Evaluation of infectious complications in patients with myelodysplastic syndromes: a prospective cohort study from the Canadian MDS registry

  2024cites this paper
• Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax.

  2024cites this paper
• Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

  2023cites this paper
• Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study

  2023cites this paper
• Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms

  2023cites this paper
• Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving calcium-calcineurin-NFAT signaling

  2023cites this paper
• DNA methyltransferase inhibitor exposure–response: Challenges and opportunities

  2023cites this paper
• Azacitidine (Vidaza^®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

  2023cites this paper
• [Treating high-risk myelodysplastic syndromes].

  2023cites this paper
• Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

  2023cites this paper
• Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database

  2023cites this paper
• Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada

  2023cites this paper
• How I Diagnose and Treat Thrombocytopenia in the Geriatric Patient.

  2023cites this paper
• Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents

  2023cites this paper
• Incidence and predisposing factors of infection in patients treated with hypomethylating agents.

  2023cites this paper
• Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine

  2023cites this paper
• What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach

  2023cites this paper
• Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study

  2022cites this paper
• Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions

  2022cites this paper
• Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM)

  2022cites this paper
• Effect of thrombopoietin receptor agonist on health-related quality of life and platelet transfusion burden for patients with myelodysplastic syndromes: a systematic review and meta-analysis

  2022cites this paper
• Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies

  2022cites this paper
• A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia

  2022cites this paper
• Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis

  2022cites this paper
• Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience.

  2022cites this paper
• Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group

  2022cites this paper
• The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs

  2022cites this paper
• Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes

  2022cites this paper
• Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience

  2022cites this paper
• A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’

  2021cites this paper
• Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T) – “2021 update on diagnosis, risk‐stratification, and management”

  2021influential citation
• Syndromes myélodysplasiques et leucémies secondaires – traitement

  2021cites this paper
• Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis

  2021cites this paper
• Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome

  2021cites this paper
• Targeting epigenetic regulatory machinery to overcome cancer therapy resistance.

  2021cites this paper
• Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis

  2021cites this paper
• Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms

  2021cites this paper
• DISSECTING THE MECHANISMS OF VENETOCLAX RESISTANCE IN MYELODYSPLASTIC SYNDROMES

  2021cites this paper
• Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.

  2021cites this paper
• Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)

  2021cites this paper
• Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.

  2021cites this paper
• Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.

  2021cites this paper
• Myelodysplastic Syndromes: A New Decade.

  2021cites this paper
• Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia

  2021cites this paper
• Molecular determinants of therapy response of venetoclax-based combinations in acute myeloid leukemia

  2021cites this paper
• Disulfiram/copper shows potent cytotoxic effects on myelodysplastic syndromes via inducing Bip-mediated apoptosis and suppressing autophagy.

  2021cites this paper
• Mutations of, methylcytosine dioxygenase TET2, polycomb group protein ASXL1 and histone‐lysine N‐methyltransferase EZH2 genes have accounted for certain subsets of triple nega‐

  2021cites this paper
• Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

  2021cites this paper
• Relationship between Low Pretreatment Geriatric Nutritional Risk Index and Poor Tolerability of Azacitidine in Patients with Myelodysplastic Syndromes

  2021cites this paper
• Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?

  2021cites this paper
• Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes

  2021cites this paper
• Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients

  2021cites this paper
• Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia

  2020cites this paper
• Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cites this paper
• The Role of Epigenetics in the Chronic Sinusitis with Nasal Polyp

  2020cites this paper
• Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome

  2020cites this paper
• CLASSIFY THE HAZARDIOUS REASONS TO TREAT PATIENTS SUFFERING MYELODYSPLASTIC DISEASE

  2020cites this paper
• Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents

  2020cites this paper
• Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies

  2020cites this paper
• IDENTIFY THE CAUSES FOR WHICH WE CANNOT TREAT PATIENTS WITH MYELODYSPLASTIC DISEASE

  2020cites this paper
• Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine

  2020cites this paper
• Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial

  2020cites this paper
• Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study

  2020cites this paper
• The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes

  2020cites this paper
• Hypomethylating Agents Use in Acute Myeloid Leukemia: A Single-Center Experience

  2020cites this paper
• Identification of DNA methylation-driven genes by integrative analysis of DNA methylation and transcriptome data in pancreatic adenocarcinoma

  2020cites this paper
• Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes

  2020cites this paper
• How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic review

  2020cites this paper
• Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors

  2020cites this paper
• JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-6 myelodysplastic syndromes (MDS)

  2020cites this paper
• Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.

  2020cites this paper
• TheraPeUTic ePigeneTics – a BOOn TO The FUTUre ?

  2020cites this paper
• Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation

  2020cites this paper
• Novel therapies in myelodysplastic syndromes.

  2020cites this paper
• Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia.

  2020cites this paper
• Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes

  2020cites this paper
• Myelodysplastic syndromes: moving towards personalized management

  2020cites this paper
• Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.

  2019cites this paper
• Mutation-Driven Therapy in MDS

  2019cites this paper
• A personalized approach to acute myeloid leukemia therapy: current options

  2019cites this paper
• Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: “2019 Update on Diagnosis, Risk‐stratification, and Management”

  2019influential citation
• Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

  2019cites this paper
• A personalized approach to acute myeloid leukemia therapy: current options

  2019cites this paper
• A Risk-Scoring System to Predict Heart Failure Onset during Treatment of Myelodysplastic Syndrome with Azacitidine

  2019cites this paper
• Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine

  2019cites this paper
• Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome

  2019cites this paper
• Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia

  2019cites this paper